398 related articles for article (PubMed ID: 34456918)
1. Coadministration of Anti-Viral Monoclonal Antibodies With Routine Pediatric Vaccines and Implications for Nirsevimab Use: A White Paper.
Esposito S; Abu-Raya B; Bonanni P; Cahn-Sellem F; Flanagan KL; Martinon Torres F; Mejias A; Nadel S; Safadi MAP; Simon A
Front Immunol; 2021; 12():708939. PubMed ID: 34456918
[TBL] [Abstract][Full Text] [Related]
2. An insect cell derived respiratory syncytial virus (RSV) F nanoparticle vaccine induces antigenic site II antibodies and protects against RSV challenge in cotton rats by active and passive immunization.
Raghunandan R; Lu H; Zhou B; Xabier MG; Massare MJ; Flyer DC; Fries LF; Smith GE; Glenn GM
Vaccine; 2014 Nov; 32(48):6485-92. PubMed ID: 25269094
[TBL] [Abstract][Full Text] [Related]
3. RSV Prevention in All Infants: Which Is the Most Preferable Strategy?
Esposito S; Abu Raya B; Baraldi E; Flanagan K; Martinon Torres F; Tsolia M; Zielen S
Front Immunol; 2022; 13():880368. PubMed ID: 35572550
[TBL] [Abstract][Full Text] [Related]
4. Passive and active immunization against respiratory syncytial virus for the young and old.
Villafana T; Falloon J; Griffin MP; Zhu Q; Esser MT
Expert Rev Vaccines; 2017 Jul; 16(7):1-13. PubMed ID: 28525961
[TBL] [Abstract][Full Text] [Related]
5. Assessment of effectiveness and impact of universal prophylaxis with nirsevimab for prevention of hospitalizations due to respiratory syncytial virus in infants. The NIRSE-GAL study protocol.
Mallah N; Ares-Gómez S; Pardo-Seco J; Malvar-Pintos A; Santiago-Pérez MI; Pérez-Martínez O; Otero-Barrós MT; Suárez-Gaiche N; Kramer R; Jin J; Platero-Alonso L; Alvárez-Gil RM; Ces-Ozores OM; Nartallo-Penas V; Mirás-Carballal S; Piñeiro-Sotelo M; González-Pérez JM; Rodríguez-Tenreiro C; Rivero-Calle I; Salas A; Durán-Parrondo C; Martinón-Torres F
Hum Vaccin Immunother; 2024 Dec; 20(1):2348135. PubMed ID: 38738683
[TBL] [Abstract][Full Text] [Related]
6. Nirsevimab Immunization to Prevent Respiratory Syncytial Virus-Associated Lower Respiratory Tract Infections in Infants and Children up to 24 Months of Age.
Cieslak CM
Nurs Womens Health; 2024 Feb; 28(1):75-79. PubMed ID: 38070539
[TBL] [Abstract][Full Text] [Related]
7. Balanced on the Biggest Wave: Nirsevimab for Newborns.
McPherson C; Lockowitz CR; Newland JG
Neonatal Netw; 2024 Apr; 43(2):105-115. PubMed ID: 38599778
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials.
Simões EAF; Madhi SA; Muller WJ; Atanasova V; Bosheva M; Cabañas F; Baca Cots M; Domachowske JB; Garcia-Garcia ML; Grantina I; Nguyen KA; Zar HJ; Berglind A; Cummings C; Griffin MP; Takas T; Yuan Y; Wählby Hamrén U; Leach A; Villafana T
Lancet Child Adolesc Health; 2023 Mar; 7(3):180-189. PubMed ID: 36634694
[TBL] [Abstract][Full Text] [Related]
9. A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants.
Zhu Q; McLellan JS; Kallewaard NL; Ulbrandt ND; Palaszynski S; Zhang J; Moldt B; Khan A; Svabek C; McAuliffe JM; Wrapp D; Patel NK; Cook KE; Richter BWM; Ryan PC; Yuan AQ; Suzich JA
Sci Transl Med; 2017 May; 9(388):. PubMed ID: 28469033
[TBL] [Abstract][Full Text] [Related]
10. Estimating the impact of multiple immunization products on medically-attended respiratory syncytial virus (RSV) infections in infants.
Rainisch G; Adhikari B; Meltzer MI; Langley G
Vaccine; 2020 Jan; 38(2):251-257. PubMed ID: 31740097
[TBL] [Abstract][Full Text] [Related]
11. Breakthrough therapy designation of nirsevimab for the prevention of lower respiratory tract illness caused by respiratory syncytial virus infections (RSV).
Bergeron HC; Tripp RA
Expert Opin Investig Drugs; 2022 Jan; 31(1):23-29. PubMed ID: 34937485
[TBL] [Abstract][Full Text] [Related]
12. Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge.
Gilbert BE; Patel N; Lu H; Liu Y; Guebre-Xabier M; Piedra PA; Glenn G; Ellingsworth L; Smith G
Vaccine; 2018 Dec; 36(52):8069-8078. PubMed ID: 30389195
[TBL] [Abstract][Full Text] [Related]
13. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn.
Pediatrics; 1998 Nov; 102(5):1211-6. PubMed ID: 9794957
[TBL] [Abstract][Full Text] [Related]
14. Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus-Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season - New Vaccine Surveillance Network, October 2023-February 2024.
Moline HL; Tannis A; Toepfer AP; Williams JV; Boom JA; Englund JA; Halasa NB; Staat MA; Weinberg GA; Selvarangan R; Michaels MG; Sahni LC; Klein EJ; Stewart LS; Schlaudecker EP; Szilagyi PG; Schuster JE; Goldstein L; Musa S; Piedra PA; Zerr DM; Betters KA; Rohlfs C; Albertin C; Banerjee D; McKeever ER; Kalman C; Clopper BR; ; McMorrow ML; Dawood FS
MMWR Morb Mortal Wkly Rep; 2024 Mar; 73(9):209-214. PubMed ID: 38457312
[TBL] [Abstract][Full Text] [Related]
15. Preventing severe respiratory syncytial virus disease: passive, active immunisation and new antivirals.
Murray J; Saxena S; Sharland M
Arch Dis Child; 2014 May; 99(5):469-73. PubMed ID: 24464977
[TBL] [Abstract][Full Text] [Related]
16. Current strategies and perspectives for active and passive immunization against Respiratory Syncytial Virus in childhood.
Scotta MC; Stein RT
J Pediatr (Rio J); 2023; 99 Suppl 1(Suppl 1):S4-S11. PubMed ID: 36402228
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of nirsevimab and palivizumab for respiratory syncytial virus prophylaxis in preterm infants 29-34 6/7 weeks' gestation in the United States.
Yu T; Padula WV; Yieh L; Gong CL
Pediatr Neonatol; 2024 Mar; 65(2):152-158. PubMed ID: 37758594
[TBL] [Abstract][Full Text] [Related]
18. Prevention of respiratory syncytial virus infections in high-risk infants by monoclonal antibody (palivizumab).
Groothuis JR; Nishida H
Pediatr Int; 2002 Jun; 44(3):235-41. PubMed ID: 11982888
[TBL] [Abstract][Full Text] [Related]
19. Neutralizing activity of anti-respiratory syncytial virus monoclonal antibody produced in
Pisuttinusart N; Rattanapisit K; Srisaowakarn C; Thitithanyanont A; Strasser R; Shanmugaraj B; Phoolcharoen W
Hum Vaccin Immunother; 2024 Dec; 20(1):2327142. PubMed ID: 38508690
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children.
Andabaka T; Nickerson JW; Rojas-Reyes MX; Rueda JD; Bacic Vrca V; Barsic B
Cochrane Database Syst Rev; 2013 Apr; (4):CD006602. PubMed ID: 23633336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]